KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

Atsushi Fujiwara^*, Masamichi Yoshida^*, Hajime Fujimoto^†, Hiroki Nakahara^†, Kentaro Ito^‡, Kota Nishihama^§, Taro Yasuma^§, Osamu Hataji^‡, Osamu Taguchi^¶, Corina N. D’Alessandro-Gabazza^§, Esteban C. Gabazza^§, Tetsu Kobayashi^†

Oncology Research, Vol.26, No.7, pp. 1031-1036, 2018, DOI:10.3727/096504018X15151523767752

Abstract Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy of NSCLC in Japan. Osimertinib can be indicated only against T790M⁺ lung cancer as a second-line therapy. However, whether gefitinib, erlotinib, or afatinib is most appropriate as a first-line therapy is still a controversial issue. The aim of this study was to compare the effectiveness of gefitinib, erlotinib, and afatinib. We retrospectively reviewed… More >

Ilias Kainis^*, Nikolaos Syrigos^*, Alexandra Kopitopoulou^*, Ioannis Gkiozos^*, Effrosyni Filiou^*, Vasiliki Nikolaou^*, Evangelia Papadavid^†

Oncology Research, Vol.26, No.1, pp. 59-69, 2018, DOI:10.3727/096504017X14913452320194

Abstract Systematic treatment of advanced non-small cell lung cancer (NSCLC) includes targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The development of skin rash and its intensity have been associated with EGFR TKI’s efficacy. The main purpose of this study was to further investigate the potential value of erlotinib-associated rash as a predictor of prognosis and treatment response in a real-world cohort of patients with advanced NSCLC. The medical records of all NSCLC patients treated with erlotinib at the Oncology Unit of GPP, Sotiria Athens General Hospital between January 1, 2014 and… More >

Arya Sobhakumari^*1, Kevin P. Orcutt^†‡1, Laurie Love-Homan^§, Christopher E. Kowalski^†‡, Arlene D. Parsons^†, C. Michael Knudson^†‡§¶, Andrean L. Simons^*†‡§¶

Oncology Research, Vol.24, No.1, pp. 55-64, 2016, DOI:10.3727/096504016X14586627440192

Abstract Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat… More >